Navigation Links
Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
Date:10/9/2008

CALGARY, Oct. 9 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the 16th Annual BioPartnering Europe conference in London, U.K. on Monday, October 13 at 2 p.m. The conference is taking place at the Queen Elizabeth II Conference Centre from October 12-14, 2008.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

The presentation time is subject to change. This release and the presentation related thereto contain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control and which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference
2. Cell Therapeutics Provides Details on Investor & Media Day to be Held in Milan, Italy on Friday, October 3, 2008
3. Huifeng Bio-pharmaceutical Technology Inc. Announces Strategic Alliance with Premier Media Service Inc.
4. U.S. News Media Group Releases 19th Edition of Americas Best Hospitals
5. VIDEO from Medialink and Med-El: New Technology is Music to Peoples Ears
6. BioLife Solutions Announces FDA Master File Acceptance for CryoStor(TM) Pre-formulated Cryopreservation Media
7. Bayer HealthCare Pharmaceuticals Introduces VistaTrak(TM) an Innovative Contrast Media Management System
8. Media Advisory - Oncolytics Biotech Inc. to Present at BioSquare 2008
9. Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
10. Intellisphere Announces Acquisition of Multiple Titles from Ascend Medias Healthcare Division
11. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)...to postmenopause , , MONTVALE, N.J., Dec. 2...nsity of vasomotor symptoms is a challenge for wom...he Journal of Family Practice have recently publi...ging the transition from perimenopause to postmeno... and Lee P. Shulman, MD, discuss the benefits of h...
(Date:12/2/2008)... -- eResearchTechnology, Inc.,(eRT), (Nasdaq: E...Clinical,technology, ePRO and other services to t...and related industries, announced today that Dr. M...hief Executive Officer, and Keith,Schneck, the Co...present at,the Piper Jaffray Health Care Conferen...
(Date:12/2/2008)...ted Cardiovascular Associates,(ACC), a 38-doctor ...tions in,Southern New Jersey, today announced tha...lth records and Sage Intergy practice management s...ich cares for more than 30,000 patients,annually,...ion to enhance care,delivery, clinical trial rese...
(Date:12/2/2008)...stCall/ -- Tianyin,Pharmaceutical, Co., Inc., (NY... modernized traditional Chinese medicine ("TCM") b...mentation of a new sales and marketing strategy to...s into three classes in order,to optimize their s...ategy has classified distributors into three class...
Breaking Biology Technology:eResearchTechnology, Inc. to Present at the Piper Jaffray Health Care Conference on December 2, 2008 2Associated Cardiovascular Consultants Selects Sage Intergy EHR to Enhance Quality, Clinical Trial Research and Physician-Patient Relationship 2Associated Cardiovascular Consultants Selects Sage Intergy EHR to Enhance Quality, Clinical Trial Research and Physician-Patient Relationship 3Associated Cardiovascular Consultants Selects Sage Intergy EHR to Enhance Quality, Clinical Trial Research and Physician-Patient Relationship 4Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth 2Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth 3
...is . - A Green Bay soil-technology company that us...products to market has won the 2006 Governor,s Sma...00 prize that comes with it. , , ENCAP, LLC , whi...nology products, was presented the award during th...ymposium presented by the Wisconsin Technology C...
...is. - CDW Corp. , the Illinois-based technology ...n Networks , is elevating a top salesman to handle...pany has put vice president of sales Steven Schuld...hnology solutions provider, into CDW. , ,CDW, head...ately-held Berbee on Oct. 11 for approximately $18...
...is. - Mirus Bio Corp. , a Madison-based biotechn... outside the U.S., that covers a method of treatin...ith an injection of genes. , ,The patent, titled "...method for delivering a wide range of therapeutic ... and compliments a patent already obtained in the ...
...is. -You,re in an elevator next to a venture capi...but doesn,t know the first thing about it yet. , ...That,s the premise of the Elevator Pitch Olympics,...osium . This year, a panel of eight investors dish...repreneurs who presented their businesses in front...
Other Biology Technology:Green Bay's ENCAP wins tech transfer award 2Mirus granted European patent for gene therapy 29 tips for making 90 seconds count in an investment pitch 2
(Date:12/1/2008)...vailable at the online site of the journal Biolog...orts for the first time that vitamin D induces imm...production of the antimicrobial protein cathelicid... trophoblast cells to the active form of vitamin D...reased antibacterial response in the trophoblast c...
(Date:12/1/2008)... The Missouri Botanical Garden Press (MBG Press) ...the species of vascular plants for the Southern Co.... Catlogo de las Plantas Vasculares del Cono Sur (... taxonomic checklist of the plants of Argentina, s...database is essentially a dictionary to the names ...
(Date:12/1/2008)..., R.I. [Brown University] Gray mold is a gardener...ific name Botrytis cinerea , is a scourge to more...s, including staples such as tomatoes, strawberrie...e, peas, peppers, and potatoes. Gray mold envelops...hat poisons the host plants, cells, eventually cau...
(Date:12/1/2008).... In the race for bioengineered crops, sequencing... multi-leg relay. Once the sequence is complete, t...ify genes, functions. A draft sequence of the soyb...me will be available soon. Taking the next step in...nary Plant Group researchers have demonstrated the...
Breaking Biology News(10 mins):Missouri Botanical Garden publishes first catalogue of plants of the Southern Cone 2Brown chemist finds gray mold's killer gene 2Tool helps identify gene function in soybeans 2Warburg Pincus Acquires 5 4 25 of WuXi PharmaTechs Outstanding Ordinary Shares from United Overseas Bank 6535 1Warburg Pincus Acquires 5 4 25 of WuXi PharmaTechs Outstanding Ordinary Shares from United Overseas Bank 6535 2Warburg Pincus Acquires 5 4 25 of WuXi PharmaTechs Outstanding Ordinary Shares from United Overseas Bank 6535 3Nets Star Josh Boone Kicks Off Free Summer Meals Program 23965 1Warfarin Safer Than Heparin for Some Strokes 23963 1Warfarin Safer Than Heparin for Some Strokes 23963 2Closing coal burning power plant in China and improved cognitive development in children 23959 1Closing coal burning power plant in China and improved cognitive development in children 23959 2Closing coal burning power plant in China and improved cognitive development in children 23959 3
...ogists at the University at Buffalo have shown for...ing antifungal agent in saliva, kills the oral pat... most HIV-related oral infections. , Researchers ...at histatin binds to a specific membrane protein c...rough the cell membrane of the pathogenic fungus C...
...tients may one day benefit from treatment with mix...ed recently in the Proceedings of the National Aca...te scientists have demonstrated how the right comb...cell,s communication network, ultimately demobiliz...research led to the identification of a family of ...
...and Drug Administration (FDA) today announced a se...ing of the non-steroidal anti-inflammatory class o...n and non-prescription (over-the-counter (OTC)) no...ducts is available on the Internet at http://www.f...ay,s actions protect and advance the health of the...
... of a new technique to map connections among nerve...Center scientist dreaming of solving the mysteries... mouse brain stimulate others, researchers in Japa...on responsible for keeping animals awake receives ... sleep, as well as reinforcing, positive signals f...
Other Biology News:Discovery may lead to better Candidiasis drug 2Two are better than one 2FDA Announces Series of Changes to the Class of Marketed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 2Brain-mapping technique aids understanding of sleep, wakefulness 2Brain-mapping technique aids understanding of sleep, wakefulness 3
Rac1/2/3 (L129) Antibody Shipping Temperature: HOT Storage Temperature: -20C
TUP1 Market Segment: Molecular Biology
UbcH7 interacts with the HECT protein, E6-AP and the c-Cbl RING domain. Evidence suggests that this E2 is involved in both the degradation of non-""N-end rule"" protein substrates and of certain N-a
COMING SOON: Anti-Mouse C5a Receptor (CD88), Clone 10/92 Monoclonal Antibody
Biology Products: